Pathos building repeatable acquisition pipeline

This points to Pathos turning Foundry into a repeatable buying engine, not just a trial optimization tool. The key shift is that the platform is now screening outside assets, matching them to specific biomarker-defined patient groups, and moving them into owned programs where Pathos keeps more of the upside. DO-2 shows the model in practice, and management tied it to three other major portfolio decisions in early 2026, which suggests a steady sourcing process rather than a rare opportunistic deal.1 2 3 4

• DO-2 is a concrete example of the workflow. Foundry identified and evaluated DeuterOncology’s MET inhibitor, Pathos then bought a majority stake, and the asset came with Phase 1 work already completed across European sites. That means the platform is not just picking ideas, it is selecting near-clinic assets that can be pulled into Pathos control quickly.1 5 6
• This makes Pathos look less like a services style AI biotech and more like an asset aggregator in oncology. The economic difference is simple. Instead of earning limited value by helping someone else run a better trial, Pathos can own or control the molecule itself and capture downstream economics across development, combinations, and label expansion.2 3 4
• The pattern also fits how the rest of the pipeline is being built. Pocenbrodib is already being pushed through biomarker-led combinations in prostate cancer, while P-500 was licensed as a Phase 2 ready PRMT5 program with plans to use AI to find higher response subgroups and additional settings. The same data layer that guides development can also guide what to acquire next.7 8

If this cadence continues, Pathos moves toward a portfolio model where Foundry continuously feeds new oncology programs into an owned pipeline. That would expand the company from improving clinical decisions on a handful of assets to systematically assembling a broader basket of mechanism specific cancer drugs, each with multiple indication paths and much larger economic ownership.1 2 3 4 7 8